Should Doximity’s Shift From Russell Growth to Value Indices Require Action From DOCS Investors?

• On 27 June 2026, Doximity, Inc. (NYSE:DOCS) was removed from several Russell growth indices and added to multiple Russell value and value‑defensive benchmarks, including the Russell 1000 Value, Russell Midcap Value and Russell 3000 Value.
• This wholesale shift from growth to value indices reframes how Doximity is categorized by index providers, potentially changing which institutional investors track the stock and how its risk profile is perceived.
• We’ll now examine how Doximity’s reclassification into value and value‑defensive Russell indices could reshape its AI-driven, healthcare-platform investment narrative.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Doximity Investment Narrative Recap

To own Doximity today, you need to believe its physician network and AI tools can keep turning engagement into durable, high quality cash flows despite slower forecast growth. The Russell shift from growth to value benchmarks mainly affects which funds track the shares; it does not materially change the near term focus on execution of its AI “third act” or the key risk around regulatory and budget pressures on pharma marketing spend.

The recent US$500.0 million buyback authorization and completion of repurchases totaling 11,604,318 shares tie directly into Doximity’s new value and value defensive label. For shareholders, this capital return program sits alongside the AI product rollout as a key near term catalyst, even as questions remain about monetizing tools like Scribe and DocsGPT while keeping margins resilient.

Yet against this backdrop of buybacks and index upgrades, investors should still be alert to the ongoing fiduciary duty investigation and potential implications for …

Read the full narrative on Doximity (it’s free!)

Doximity’s narrative projects $769.1 million revenue and $212.2 million earnings by 2029. This requires 6.0% yearly revenue growth and about a $16.1 million earnings increase from $196.1 million today.

Uncover how Doximity’s forecasts yield a $25.42 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, penciling in only about 4.4 percent annual revenue growth to roughly US$733.8 million and earnings of about US$166.9 million, and the Russell shift toward value indices could either reinforce or challenge that more pessimistic view depending on how you think Doximity’s AI spend and margins evolve from here.

Explore 4 other fair value estimates on Doximity – why the stock might be worth 18% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Doximity research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Doximity’s overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don’t miss this chance:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]